McGill University, Montreal, Quebec, Canada.
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1275-80. doi: 10.1002/acr.21966.
To examine the association between smoking and cutaneous involvement in systemic lupus erythematosus (SLE).
We analyzed data from a multicenter Canadian SLE cohort. Mucocutaneous involvement was recorded at the most recent visit using the Systemic Lupus Erythematosus Disease Activity Index 2000 Update (rash, alopecia, and oral ulcers), Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index (alopecia, extensive scarring, and skin ulceration), and the ACR revised criteria for SLE (malar rash, discoid rash, photosensitivity, and mucosal involvement). Multivariate logistic regression models were used to estimate the independent association between mucocutaneous involvement and cigarette smoking, age, sex, ethnicity, lupus duration, medications, and laboratory data.
In our cohort of 1,346 patients (91.0% women), the mean ± SD age was 47.1 ± 14.3 years and the mean ± SD disease duration was 13.2 ± 10.0 years. In total, 41.2% of patients were ever smokers, 14.0% current smokers, and 27.1% past smokers. Active mucocutaneous manifestations occurred in 28.4% of patients; cutaneous damage occurred in 15.4%. Regarding the ACR criteria, malar rash was noted in 59.5%, discoid rash in 16.9%, and photosensitivity in 55.7% of patients. In the multivariate analysis, current smoking was associated with active SLE rash (odds ratio [OR] 1.63 [95% confidence interval (95% CI) 1.07, 2.48]). Having ever smoked was associated with ACR discoid rash (OR 2.36 [95% CI 1.69, 3.29]) and photosensitivity (OR 1.47 [95% CI 1.11, 1.95]), and with the ACR total cutaneous score (OR 1.50 [95% CI 1.22, 1.85]). We did not detect any associations between previous smoking and active cutaneous manifestations. No association was found between smoking and cutaneous damage or mucosal ulcers. No interaction was seen between smoking and antimalarials.
Current smoking is associated with active SLE rash, and ever smoking with the ACR total cutaneous score. This provides additional motivation for smoking cessation in SLE.
探讨吸烟与系统性红斑狼疮(SLE)皮肤受累的关系。
我们分析了来自加拿大多中心 SLE 队列的数据。使用 2000 年系统性红斑狼疮疾病活动指数更新版(皮疹、脱发和口腔溃疡)、系统性红斑狼疮国际合作诊所/美国风湿病学会(ACR)损害指数(脱发、广泛瘢痕和皮肤溃疡)和 ACR 修订的 SLE 标准(蝶形皮疹、盘状皮疹、光敏感和黏膜受累)来记录最近一次就诊时的黏膜皮肤受累情况。采用多变量逻辑回归模型来估计黏膜皮肤受累与吸烟、年龄、性别、种族、狼疮病程、药物和实验室数据之间的独立关联。
在我们的 1346 名患者(91.0%为女性)队列中,平均年龄±标准差为 47.1±14.3 岁,平均病程±标准差为 13.2±10.0 年。共有 41.2%的患者曾吸烟,14.0%的患者目前吸烟,27.1%的患者曾经吸烟。28.4%的患者有活动性黏膜皮肤表现,15.4%的患者有皮肤损害。根据 ACR 标准,59.5%的患者有蝶形皮疹,16.9%的患者有盘状皮疹,55.7%的患者有光敏感。在多变量分析中,目前吸烟与 SLE 皮疹活动(比值比[OR]1.63[95%置信区间(95%CI)1.07,2.48])相关。曾吸烟与 ACR 盘状皮疹(OR 2.36[95%CI 1.69,3.29])和光敏感(OR 1.47[95%CI 1.11,1.95])以及 ACR 总皮肤评分(OR 1.50[95%CI 1.22,1.85])相关。我们没有发现既往吸烟与活动性皮肤表现之间的任何关联。吸烟与皮肤损害或黏膜溃疡之间也没有关联。我们没有发现吸烟与抗疟药之间的相互作用。
目前吸烟与 SLE 皮疹活动有关,而既往吸烟与 ACR 总皮肤评分有关。这为 SLE 患者戒烟提供了额外的动力。